A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-05-12
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-21 (study day 50); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 73); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 156); relationship: N
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-06 (study day 188); relationship: not assessed; serious criteria: hospitalization
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-07 (study day 189); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 209); relationship: N
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 212); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-01 (study day 214); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-07 (study day 251); relationship: not assessed
Data queries
No data queries.